Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2623480 | 1.00 | BRD4 (0.39) | BRD4MIFTSHRHSD17B10CYP3A4 | |
| SCHEMBL22362233 | 0.77 | SLC6A12 (0.35) | MAPT | |
| SCHEMBL321972 | 0.72 | — | — | |
| SCHEMBL12050773 | 0.70 | — | — | |
| SCHEMBL12050772 | 0.70 | — | — | |
| SCHEMBL24197361 | 0.69 | BRD4 (0.50) | BRD4TSHRHSD17B10CYP3A4MAPT | |
| SCHEMBL24942605 | 0.69 | — | — | |
| SCHEMBL26647720 | 0.69 | BRD4 (0.50) | BRD4TSHRHSD17B10CYP3A4MAPT | |
| SCHEMBL24943082 | 0.69 | — | — | |
| SCHEMBL2036054 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101257-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | UNIVERSITE DE MONTREAL (CA) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101257-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | QPCT, GLUL, ASNS | BRD4 4647/4885MIF 3155/4885TSHR 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.